Production and immunogenicity of different prophylactic vaccines for hepatitis C virus (Review)

Exp Ther Med. 2022 May 30;24(1):474. doi: 10.3892/etm.2022.11401. eCollection 2022 Jul.

Abstract

Hepatitis C virus (HCV) infection is a global health challenge, and prophylactic vaccines are the most effective way to eliminate the infection. To date, numerous forms of preventive vaccines have entered the clinical trial stage, including the virus-like particle (VLP) vaccine, recombinant subunit vaccine, peptide vaccine and nucleic acid vaccine. The rational design makes it easier to obtain specific vaccine structures with a broad spectrum and strong immunogenicity. Different vaccine antigens can evoke different immune responses, including humoral and T-cell immune responses, and can be produced using different expression systems, such as bacteria, yeast, mammals, plants, insects or parasites. Intracellular and insoluble production and a narrow immune spectrum are two difficulties that limit the application of vaccines. The present study summarizes the immunogenicity of different preventive vaccines, evaluates the characteristics of different expression systems used for vaccine production, and analyzes the strategies to enhance the secretion and immune spectrum of vaccine proteins.

Keywords: hepatitis C virus; immune spectrum; immunogenicity; production; secretion; vaccine.

Publication types

  • Review

Grants and funding

Funding: This present study was supported by the Shandong Key Research and Development Fund (grant no. 2018GSF121011), the Jinan Clinical Medical Science and Technology Innovation Fund (grant no. 201805066) and the High-Level Project Cultivation Fund of Jinan Central Hospital (grant no. 202105006).